Clinical trial
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic…
NCT00475423 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00475423 |
|---|---|
| Title | A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. |
| Official title | An Open Label Study of a Fixed Dose Regimen of MabThera on Overall Response Rate in Patients With Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura. |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Idiopathic Thrombocytopenic Purpura |
| Intervention type | Drug |
| Interventions | rituximab [MabThera/Rituxan] |
| Enrollment | 122 |
| Start date | May 1, 2007 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | May 21, 2007 |
| Last update posted | Feb 23, 2015 |
| Countries | Australia |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: